| 摘要 |
FIELD: medicine, pulmonology, allergology. ^ SUBSTANCE: the present innovation deals with treating asthma due to introducing parabrominephenacyl bromide (PBPB) at the dosages ranged 0.1-10 mg/kg body weight. Therapeutic course lasts about 1 wk. The innovation in question provides efficient therapy due to inhibiting phospholipase A2 with PBPB in the dosages and the mode mentioned. ^ EFFECT: higher efficiency of prophylaxis and therapy. ^ 36 cl, 8 dwg, 8 ex, 1 tbl |
